IgA肾病易感基因位点与疾病进展的关联
该研究纳入613例成人IgA肾病患者随访≥12个月,对20个易感位点进行基因分型,经质控后16个SNP和517例患者纳入分析。逐步Cox回归筛选出四SNP模型(rs11150612、rs7634389、rs2412971、rs2856717),其遗传风险评分与疾病进展独立相关,并可提升临床及临床-病理模型的预测区分度。
要点
- 四SNP遗传风险评分与IgA肾病进展独立相关。
- 中、高遗传风险者进展风险分别增加2.12倍和3.61倍。
- 加入遗传评分可提升临床模型对5年进展风险的区分度。
核心结论
- 四SNP遗传风险评分与IgA肾病进展独立相关,并能提升临床及临床-病理风险模型的预测性能。
研究设计与样本
- 纳入613例成人IgA肾病患者随访≥12个月,对20个易感位点标签SNP进行基因分型,经质控后16个SNP和517例患者纳入分析。
- 进展定义为ESKD或eGFR下降50%,采用基于Akaike信息准则的逐步Cox回归选择最佳模型。
主要发现
- 四SNP模型(rs11150612、rs7634389、rs2412971、rs2856717)被选为最佳预测模型。
- 遗传风险评分与疾病进展独立相关:未调整HR 1.65(95%CI 1.29–2.12),经临床模型调整后HR 1.29(95%CI 1.03–1.62),经临床-病理模型调整后HR 1.35(95%CI 1.03–1.77)。
- 与低遗传风险相比,中遗传风险进展风险增加2.12倍(95%CI 1.33–3.40),高遗传风险增加3.61倍(95%CI 2.00–6.52)。
- 纳入遗传风险评分可潜在提升临床模型(c统计量从0.83升至0.86)或临床-病理模型(c统计量从0.82升至0.85)对5年进展风险的区分度。
临床怎么用
- 对IgA肾病患者可考虑检测四SNP遗传风险评分,辅助临床及临床-病理模型进行进展风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: At least 20 susceptibility loci of IgA nephropathy have been identified by genome-wide association studies to date. Whether these loci were associated with disease progression is unclear. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We enrolled 613 adult patients with IgA nephropathy for a follow-up of ≥12 months. All 20 IgA nephropathy susceptibility loci were selected and their tag single nucleotide polymorphisms (SNPs) were genotyped. After strict quality control, 16 SNPs and 517 patients with IgA nephropathy were eligible for subsequent analysis. Progression was defined as ESKD or 50% decrease in eGFR. A stepwise Cox regression analysis of all SNPs on Akaike information criterion was performed to select the best model. RESULTS: A four-SNP model, rs11150612 (ITGAM-ITGAX), rs7634389 (ST6GAL1), rs2412971 (HORMAD2), and rs2856717 (HLA-DQ/DR), was selected as the best predictive model. The genetic risk score calculated on the basis of the four SNPs was independently associated with disease progression before (hazard ratio [HR], 1.65; 95% confidence interval [95% CI], 1.29 to 2.12) and after adjustment by a recently reported clinical model (HR, 1.29; 95% CI, 1.03 to 1.62) or clinical-pathologic model (HR, 1.35; 95% CI, 1.03 to 1.77). Compared with low genetic risk, patients with middle genetic risk had a 2.12-fold (95% CI, 1.33 to 3.40) increase of progression risk, whereas patients with high genetic risk had 3.61-fold (95% CI, 2.00 to 6.52) progression risk increase. In addition, incorporation of genetic risk score could potentially increase discrimination of the clinical model (c-statistic increase from 0.83 to 0.86) or the clinical-pathologic model (c-statistic increase from 0.82 to 0.85) in predicting 5-year progression risk. CONCLUSIONS: The four-SNP genetic risk score was independently associated with IgA nephropathy progression and could enhance the performance of clinical and clinical-pathologic risk models.
引用
- Shi M, Ouyang Y, Yang M, et al. IgA Nephropathy Susceptibility Loci and Disease Progression. Clin J Am Soc Nephrol. 2018. PMID: 30042224. doi:10.2215/CJN.13701217
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。